- Home
- XFOR vs NKTR Comparison
XFOR vs NKTR Comparison
Compare XFOR & NKTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XFOR
- NKTR
- Stock Information
- Founded
- XFOR 2014
- NKTR 1990
- Country
- XFOR United States
- NKTR United States
- Employees
- XFOR N/A
- NKTR N/A
- Industry
- XFOR Biotechnology: Biological Products (No Diagnostic Substances)
- NKTR Biotechnology: Pharmaceutical Preparations
- Sector
- XFOR Health Care
- NKTR Health Care
- Exchange
- XFOR Nasdaq
- NKTR Nasdaq
- Market Cap
- XFOR 118.4M
- NKTR 108.3M
- IPO Year
- XFOR N/A
- NKTR 1994
- Fundamental
- Price
- XFOR $1.48
- NKTR $24.25
- Analyst Decision
- XFOR Strong Buy
- NKTR Strong Buy
- Analyst Count
- XFOR 3
- NKTR 6
- Target Price
- XFOR $72.33
- NKTR $81.67
- AVG Volume (30 Days)
- XFOR 466.4K
- NKTR 4.8M
- Earning Date
- XFOR 08-07-2025
- NKTR 08-07-2025
- Dividend Yield
- XFOR N/A
- NKTR N/A
- EPS Growth
- XFOR N/A
- NKTR N/A
- EPS
- XFOR 2.16
- NKTR N/A
- Revenue
- XFOR $31,364,000.00
- NKTR $87,248,000.00
- Revenue This Year
- XFOR $1,106.53
- NKTR N/A
- Revenue Next Year
- XFOR N/A
- NKTR N/A
- P/E Ratio
- XFOR $0.66
- NKTR N/A
- Revenue Growth
- XFOR N/A
- NKTR N/A
- 52 Week Low
- XFOR $1.41
- NKTR $6.48
- 52 Week High
- XFOR $26.96
- NKTR $37.38
- Technical
- Relative Strength Index (RSI)
- XFOR 25.85
- NKTR 63.40
- Support Level
- XFOR $1.81
- NKTR $21.87
- Resistance Level
- XFOR $2.12
- NKTR $26.59
- Average True Range (ATR)
- XFOR 0.21
- NKTR 4.14
- MACD
- XFOR -0.01
- NKTR 0.01
- Stochastic Oscillator
- XFOR 1.88
- NKTR 54.77
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in the research and development of novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It has the ability to increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
About NKTR Nektar Therapeutics
Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy. The company is focused on discovering and developing medicines in the field of immunotherapy. Its pipeline products are REZPEG (NKTR-358), REZPEG (NKTR-358), REZPEG (NKTR-358), NKTR-422, NKTR-0165, NKTR-255, and Others.